Language: BG BG
← Back to results
Recruiting Phase 3 2024-518835-13-00

A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease

Phase 3 – large-scale trial before approval
Conditions: Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar) peripheral or abdominal/renal arteries

Sponsor: Guerbet, Bracco Imaging S.p.A.

trial.available_in: БГ
Overview
Trial status: Authorised Diagnostic performance indicators, namely sensitivity and specificity for detecting clinically significant steno-occlusive disease of different vascular territories.
Who can participate
Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 300 participants
Interventions
DOTAREM 0,5 mmol/mL, solution injectable
Drug
GADOPICLENOL
Drug
Locations 7
Czech Republic (1)
France (1)
Germany (1)
Hungary (1)
Italy (1)
Poland (1)
Spain (1)
Technical details
Status
Recruiting
Phase
Phase 3
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
15.04.2026
Registry ID
2024-518835-13-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.